On 2/28/2017, Citigroup Inc released a statement for Esperion Therapeutics (NASDAQ:ESPR) bumped up the target price from $14.00 to $39.00 that suggested an upside of 0.25%. Seven analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company's outstanding shares are 23.53 Million. Advisor Group Inc. now owns 14,437 shares of the biopharmaceutical company's stock valued at $200,000 after buying an additional 85 shares during the last quarter. The difference between the expected and actual EPS was $-0.07/share, which represents an Earnings surprise of -5.7%. Likewise, the positive performance for the quarter was recorded as 92.60% and for the year was 64.60%, while the YTD performance remained at 89.06%. The stock has a market cap of 556.96 Million.
ESPR), the lipid administration company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), recently declared the initiation of a Phase 2 clinical study (1002-038) to assess the efficacy and safety of triplet oral therapy with bempedoic acid, ezetimibe and atorvastatin in patients with hypercholesterolemia.
Which Way is The Street Betting Esperion Therapeutics, Inc. Keybank National Association OH purchased a new position in Esperion Therapeutics during the fourth quarter worth about $159,000. The volume of the company in the last trading session was 9.48 Million. Esperion Therapeutics, Inc. (NASDAQ:ESPR)'s EPS growth this year is -47.10% and the trailing 12-month EPS is $-3.33. Virginia Retirement Systems ET AL acquired a new position in shares of Esperion Therapeutics during the third quarter valued at $242,000. The stock's current distance from 20-Day Simple Moving Average (SMA20) is -16.97% where SMA50 and SMA200 are 17.71% and 65.99% respectively. Finally, Dimensional Fund Advisors LP increased its position in shares of Esperion Therapeutics by 54.9% in the fourth quarter. During the same period in the prior year, the firm earned ($0.58) earnings per share. On average, equities research analysts anticipate that Esperion Therapeutics will post ($6.04) earnings per share for the current fiscal year.
During earlier studies, the drug decreased cholesterol biosynthesis and brought down higher levels of LDL-C, and was also believed to potentially decrease the occurrence of muscle-related side effects.